Vizsgálati helyszín
Clinica Universitaria de Navarra
Pamplona, Navarre 31008, SpanyolországMég nincs intézményhez kötve
- 12futó vizsgálat
- 19lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 31 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis10 vizsgálat
- 1. fázis7 vizsgálat
- 2. fázis7 vizsgálat
- 1/2. fázis2 vizsgálat
- Állapot
- Lezárult16 vizsgálat
- Fut, nem toboroz6 vizsgálat
- Toboroz4 vizsgálat
- Még nem toboroz2 vizsgálat
- Leállították2 vizsgálat
- Visszavonták1 vizsgálat
- Fő szponzor
- Hoffmann-La Roche15 vizsgálat
- Genentech, Inc.3 vizsgálat
- PETHEMA Foundation3 vizsgálat
- Replimune, Inc.2 vizsgálat
- Daiichi Sankyo1 vizsgálat
- és még 7
Futó vizsgálatok
Toboroz
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)
NCT07478991· 3. fázis· PETHEMA Foundation· Forrás
Contact: Ana Alfonso Piérola
Toboroz
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· 3. fázis· Hoffmann-La Roche· Forrás
Még nem toboroz
Study to Evaluate the Safety and Efficacy of ARI0002h, for the Initial Treatment of Patients With Primary Plasma Cell Leukaemia
NCT06830733· 2. fázis· Fundacion Clinic per a la Recerca Biomédica· Forrás
Contact: Paula Rodríguez Otero
Toboroz
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT06004245· 1. fázis· Vividion Therapeutics, Inc.· Forrás
Toboroz
Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA)
NCT06379945· Instituto de Investigación Biomédica de Salamanca· Forrás
Contact: Felipe López Cardoso, PhD
Fut, nem toboroz
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
NCT04140500· 1/2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years
NCT03742297· 3. fázis· PETHEMA Foundation· Forrás
Fut, nem toboroz
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
NCT03595592· 3. fázis· Fondazione Michelangelo· Forrás
Fut, nem toboroz
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
NCT03589222· 2. fázis· PETHEMA Foundation· Forrás
Fut, nem toboroz
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348· 2. fázis· Replimune, Inc.· Forrás
Fut, nem toboroz
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
NCT03148418· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Thoracic Tumours Register
NCT02941458· Spanish Lung Cancer Group· Forrás
Contact: Ignacio Gil-Bazo, MD
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A Study Conducted to Evaluate the Conjunctiva and Tenon's Capsule Status of Healthy Subjects and in Participants With Neovascular Age-related Macular Degeneration (nAMD)/Diabetic Macular Edema (DME)
NCT06723288· Hoffmann-La Roche· Forrás
Visszavonták
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
NCT05743270· 2. fázis· Replimune, Inc.· Forrás
Lezárult
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
NCT05867121· 1. fázis· Genentech, Inc.· Forrás
Lezárult
A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)
NCT05258071· 2. fázis· Integrative Research Laboratories AB· Forrás
Lezárult
A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma
NCT05187624· 1. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema
NCT05151744· 2. fázis· Hoffmann-La Roche· Forrás
Leállították
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
NCT04963270· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment
NCT04826003· 1. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT04777201· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
NCT04744831· 2. fázis· Daiichi Sankyo· Forrás
Lezárult
A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer
NCT04468607· 1. fázis· Genentech, Inc.· Forrás
Leállították
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
NCT03869190· 1/2. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
NCT03782207· Hoffmann-La Roche· Forrás
Lezárult
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
NCT03708328· 1. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
NCT03289962· 1. fázis· Genentech, Inc.· Forrás
Lezárult
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
NCT03072238· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
NCT02908672· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
NCT02807636· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
NCT01454297· Multiple Myeloma Research Foundation· Forrás
Hibát jelzek